| Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA |
2018-12-05 |
| CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG |
2018-12-05 |
| Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG |
2018-12-05 |
| Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH |
2018-12-05 |
| Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH |
2018-12-05 |
| Merck (DE)–V7: AI software, 201812– collab on software that scientists can use to tag images for future use in training AI software |
2018-12-05 |
| Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH |
2018-12-05 |
| Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH |
2018-12-05 |
| Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF |
2018-12-04 |
| Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs |
2018-12-04 |
| Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets |
2018-12-04 |
| Dispendix–Cellink: investment, 201812 acquisition €5m of Dispendix GmbH by Cellink AB |
2018-12-01 |
| CureVac–Piper Jaffray: investor conference, 201811 supply service CureVac presents at Piper Jaffray Healthcare Conference 2018 |
2018-11-27 |
| Spindiag–SEVERAL: investment, 201811 financing round Series A €3m |
2018-11-27 |
| Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments |
2018-11-26 |
| Adrenomed–MC Services: public relations, 201811 service existent by MC Services |
2018-11-26 |
| Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors |
2018-11-26 |
| Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners |
2018-11-26 |
| Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development |
2018-11-26 |
| Suntory–BRAIN Biotech: food ingredients, 201811– collab €na developm natural beverage solutions with SBFE |
2018-11-26 |
| Evotec–Immuneering: drug discovery software, 201811– collab AI-driven small-molecule drug discovery for hereditary metabolic diseases |
2018-11-21 |
| Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen |
2018-11-20 |
| Boehringer–Epizyme: small-molecule cancer drugs, 201811– collab strategic ww to develop inhibitors toward two epigenetic targets |
2018-11-15 |
| I-Mab–MorphoSys: antibody cancer drug, 201811– license excl Greater China + KR for MOR210 with $3.5m upfront + $101.5m milestones + royalties |
2018-11-15 |
| Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic |
2018-11-14 |
| BioNTech–Univ Pennsylvania: mRNA technology, 201811– strategic research collab €na to develop mRNA vaccines for infectious disease |
2018-11-05 |
| Immunic–Daiichi Sankyo: IMU-856, 201811– license option agreem ww excl to in-license + develop IMU-856 program for IBD |
2018-11-05 |
| Omeicos–Forbion: investment, 201811 financing round Series C totalling €17m incl new + lead investor Forbion |
2018-11-02 |
| Omeicos–SEVERAL: investment, 201811 financing round Series C €17m led by new investor Forbion |
2018-11-02 |
| HBM–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D round |
2018-11-01 |
| Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins |
2018-11-01 |
| Wellington Partners–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D |
2018-11-01 |
| Grünenthal–AstraZeneca: esomeprazole, 201810– acquisition $922m of European rights to Nexium + ww ex US+JP rights to Vimovo |
2018-10-30 |
| Noscendo–SEVERAL: investment, 201810 financing round €7-digit led by Wieland Capital + incl HTGF + three business angels |
2018-10-29 |
| BASF–MIT: CRISPR technology, 201810– license ww non-excl to CRISPR-Cpf1 technology from Broad Institute for agriculture + industrial microbiology |
2018-10-24 |
| Genome Biologics (DE)–EU (govt): grant, 201810 Horizon 2020 Phase 2 Grant €2.42m |
2018-10-22 |
| Kumovis–Ffilipa Venture Capital: investment, 201810 seed financing round totalling 7-digit € incl family office |
2018-10-17 |
| Kumovis–High-Tech Gründerfonds: investment, 201810 seed financing round totalling 7-digit € incl investor HTGF |
2018-10-17 |
| Kumovis–SEVERAL: investment, 201810 seed financing round 7-digit € from HTGF + Ffilipa Venture Capital |
2018-10-17 |
| Oncgnostics–Thuringia (govt): investment, 201810 additional investment of €750k from bm|t + private investors |
2018-10-17 |
| Quantum Analytics–Bruker: analytical instruments, 201810– distribution of S2 Puma + S2 Polar + D2 Phaser analysers in the US by Quantum Analytics |
2018-10-16 |
| LaVision BioTec–Miltenyi Biotec: investment, 201810 acquisition of LaVision BioTec GmbH by Miltenyi |
2018-10-12 |
| Gotham Therapeutics–MacDougall Biomedical Communications: public relations, 201810 service existent by MacDougall |
2018-10-10 |
| SmartDyeLivery–PERSON: investment, 201810 financing round from bm|t + business angel from Munich |
2018-10-10 |
| SmartDyeLivery–SEVERAL: investment, 201810 financing round from bm|t + business angel from Munich |
2018-10-10 |
| SmartDyeLivery–Thuringia (govt): investment, 201810 financing round from bm|t + business angel from Munich |
2018-10-10 |
| DSM–Lipotype: mass spectrometry services, 201810 collab supply of shotgun skin lipidomics services by Lipotype to Royal DSM |
2018-10-08 |
| Lipoid–Lipotype: mass spectrometry services, 201810 collab supply of shotgun skin lipidomics services by Lipotype to Lipoid GmbH |
2018-10-08 |
| Sphingotec–HBM: investment, 201810 financing round totalling €20m incl co-lead investor HBM |
2018-10-08 |
| Sphingotec–SEVERAL: investment, 201810 financing round €20m co-led by HBM + Wellington Partners |
2018-10-08 |
| Sphingotec–Wellington Partners: investment, 201810 financing round totalling €20m incl co-lead investor Wellington Partners |
2018-10-08 |
| Sanofi–Evotec: drug discovery, 201810– collab partnership BRIDGE LAB031 for early-stage projects out of academic research |
2018-10-04 |
| Oncgnostics–Biotech Alliances International: business services, 201810– supply service support for global partnering + distribution strategy |
2018-10-02 |
| Atai Life Sciences–SEVERAL: investment, 201810 1st financing round €21.2m from private investors |
2018-10-01 |
| B Braun–CeGaT: personalised medicine, 201810 collab establishment JV to develop personalised cancer vaccines CeCaVa GmbH & Co KG |
2018-10-01 |
| Evotec–Cantor Fitzgerald: investor conference, 201809 supply service Evotec presents at Cantor Fitzegerald Global Healthcare Conference in NY |
2018-10-01 |
| Helmholtz–Bruker: MRI system, 201810 supply 9.4 Tesla preclinical MRI system with integrated PET detector to DKFZ |
2018-10-01 |
| Novaliq–Hopp Group: investment, 201810 financing round €44.9m from Dievini Hopp BioTech Holding GmbH |
2018-10-01 |
| Strüngmann Group–Cyclenium: anti-infectives, 201810– collab discovery using CMRT technology + QUEST Library with AiCuris |
2018-10-01 |
| Pfizer–Qiagen: companion diagnostics, 201809 collab existent CDx for precision medicines in onocology |
2018-09-28 |
| Bayer–Genedata: bioinformatics, 201809– license to Genedata Selector s/w for Bayer CropScience division for develop new fungicides |
2018-09-27 |
| Bayer–Inova Software: business development software, 201809 supply existent Bayer is user of Inova Partnering Platform |
2018-09-27 |
| Evotec–Berenberg: investor conference, 201809 supply service Evotec attends 7th German Corporate Conference in Munich |
2018-09-26 |
| Evotec–Baader Bank: investor conference, 201809 supply service Evotec attends Baader Investment Conference 2018 in Munich |
2018-09-24 |
| Plug and Play–Roche: healthcare, 201809–202108 collab creation of Startup Creasphere innovation program in Munich with Roche Diagnostics |
2018-09-20 |
| BluCon Biotech–BRAIN Biotech: industrial biotechnology, 201809– strategic research collab microbial strain developm for PLA-based bioplastic |
2018-09-18 |
| Almirall–Evotec: drug discovery services, 201809– collab RnD therapies for dermatological diseases |
2018-09-17 |
| Evotec–Morgan Stanley: investor conference, 201809 supply service Evotec presents at Morgan Stanley Global Healthcare Conference NY |
2018-09-13 |
| Evotec–JPMorgan Chase: investor conference, 201809 supply service Evotec at JP Morgan Cazenove Pan-European Small/Mid Cap Conference London |
2018-09-12 |
| Merck (DE)–AstraZeneca: digital pathology, 201809– collab multi-year partnership with Definiens using TissuePhenomics for biomarker quantification |
2018-09-10 |
| RSP Systems–Trumpf: investment, 201809 financing round Series B 2nd closing totalling €3.85m incl new investor Trumpf Venture GmbH |
2018-09-10 |
| Evotec–Goldman Sachs: investor conference, 201809 supply service Evotec at 8th Annual Biotech Symposium in London |
2018-09-07 |
| Affimed–Wells Fargo: investor conference, 201809 supply service Affimed presents at Wells Fargo Healthcare Conference in Boston |
2018-09-06 |
| Celgene–Evotec: drug discovery services, 201809– strategic RnD collab in field of targeted protein degradation using Panomics platform |
2018-09-06 |
| Mologen–SEVERAL: investment, 201809 capital increase €8.2m with 1.73m new shares at €4.7/share to existing + new investors |
2018-09-03 |
| CHDI–Evotec: drug discovery services, 201808–2023 collab service extension CHDI funding up to 75 full-time scientists for Huntington’s disease drugs |
2018-08-30 |
| Nebula Genomics–Heartbeat Labs: investment, 201808 seed financing round totalling $4.3m incl Heartbeat Labs |
2018-08-29 |
| Evotec–Centogene: drug discovery, 201808– collab ww strategic €na discovery + developm of treatments for rare genetic diseases |
2018-08-27 |
| Roche–Affimed: antibody cancer drug, 201808– collab $96m ufpront + $5b milestones + royalties using ROCK platform to develop ABs with Genentech |
2018-08-27 |
| Hain Lifescience–Bruker: investment, 201808– acquisition €na of 80% majority interest with option to acquire rest in 2012 ANNOUNCED |
2018-08-24 |
| c-LEcta–Capricorn Venture Partners: investment, 201808 financing round incl new + lead investor Capricorn investing via CSCF NV + Quest for Growth |
2018-08-23 |
| c-LEcta–SEVERAL: investment, 201808 financing round €na with new investors Capricorn Venture Partners + bm|t |
2018-08-23 |
| c-LEcta–Thuringia (govt): investment, 201808 financing round incl new + co-investor bm|t via MFT Mittelstands-Fonds Thüringen |
2018-08-23 |
| Merck (DE)–GlucoMe: digital health, 201808– collab digital diabetes management project in Vietnam |
2018-08-22 |
| Novo Group–Evotec: drug discovery services, 201808– collab €na strategic alliance RnD small molecule drugs for diabetes + obesity Novo Nordisk |
2018-08-22 |
| SolasCure–Brain Biotech: investment, 201808–202108 financing round Series A totalling £15m incl lead investor Brain Biotech AG |
2018-08-22 |
| SolasCure–BRAIN Biotech: wound care product, 201808– license IP for Aurase enzyme + supply of enzymatic active ingredient by BRAIN to SolasCure |
2018-08-22 |
| Oncologie–Mologen: lefitolimod, 201808–201811 term sheet for acquisition of ww rights to lefitolimod by Oncologie TERMINATED 11/18 |
2018-08-15 |
| Bayer–Haplogen: antiviral agents, 201808– collab €na developm candidates for pulmonary diseases incl COPD |
2018-08-14 |
| Univ Warwick–Bruker: NMR spectrometer, 201808 supply Avance 1.0 GHz solid-state NMR spectrometer |
2018-08-06 |
| Miraca–Qiagen: molecular companion diagnostics, 201808– collab with SRL to introduce of CDx tests in Japan in line with respective drug approvals |
2018-08-01 |
| Bayer–Leo Pharma: investment, 201807–201907 acquisition of global prescription dermatology business of Bayer |
2018-07-31 |
| Biocrates–MC Services: public relations, 201807 service existent by MC Services |
2018-07-25 |
| SHS Capital–SEVERAL: investment, 201807 first closing €90m of SHS V fund with target size of €150m |
2018-07-20 |
| Novartis–MorphoSys: therapeutic antibody, 201807– license excl ww to MOR106 from MOR+GLPG €95m upfront + €850m milestones + royalties + funding |
2018-07-19 |
| Adocia–MC Services: public relations, 201807 service existent PR Europe by MC Services |
2018-07-18 |
| Beiersdorf–S-Biomedic: skin microbiomics, 201807– collaboration |
2018-07-18 |
| DCPrime–Glycotope: cancer immunotherapy, 201807– license + collab agreement research new approaches to solid tumours |
2018-07-18 |
| S-Biomedic–Beiersdorf: investment, 201807 financing round Series A 1st closing totalling €2m incl lead investor Beiersdorf AG |
2018-07-18 |
| B Braun–CeGaT: personalised medicine, 201807 collab establishment of B Braun Precision Medicine Technology (Shanghai) Ltd |
2018-07-17 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
